As NL­RP3 play­ers head for first clin­i­cal face-off, No­vo, Sanofi fu­el trans-At­lantic con­tender with $55M

In the rel­a­tive short his­to­ry of in­flam­ma­some re­search, Adam Keeney sees two time points mark­ing ma­jor break­throughs: the ear­ly 2000s, when the role of in­flam­ma­somes as a ma­jor in­nate im­mu­ni­ty node was elu­ci­dat­ed; and 2015, when sci­en­tists ob­served that an old Pfiz­er com­pound they thought were block­ing IL-1 ac­tu­al­ly tar­get­ed NL­RP3. Keeney’s biotech, NodThera, was found­ed the year af­ter along­side sev­er­al oth­ers to cre­ate its own su­pe­ri­or small mol­e­cule drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER